官方微信|手機版|本站服務(wù)|買家中心|行業(yè)動態(tài)|幫助

產(chǎn)品|公司|采購|招標

伊洛前列素 Iloprost

參考價面議
具體成交價以合同協(xié)議為準
  • 公司名稱臺州市科瑞生物技術(shù)有限公司
  • 品       牌其他品牌
  • 型       號cas 78919-13-8
  • 所  在  地臺州市
  • 廠商性質(zhì)生產(chǎn)廠家
  • 更新時間2020/8/28 15:09:23
  • 訪問次數(shù)420
產(chǎn)品標簽:

伊洛前列素

在線詢價 收藏產(chǎn)品 查看電話 同類產(chǎn)品

聯(lián)系我們時請說明是 制藥網(wǎng) 上看到的信息,謝謝!

臺州市科瑞生物技術(shù)有限公司一家致力于醫(yī)藥產(chǎn)品的研發(fā)、生產(chǎn)、銷售于一體的高科技有限責(zé)任公司,緊跟上市新藥,專注于小分子抑制劑產(chǎn)品。公司擁有合成實驗室、分析實驗室、成鹽和晶型實驗室等;實驗室配套設(shè)備齊全,擁有有高低溫一體機、50L和100L反應(yīng)釜、100L氫化反應(yīng)釜等儀器.配備了專業(yè)的分析檢測儀器,包括安捷倫的液質(zhì)聯(lián)用、安捷倫高效液相、島津高效液相、高效制備色譜儀,水分測定儀、賽多利斯分析天平等,公司對每個產(chǎn)品進行嚴格的分析檢測,確保產(chǎn)品符合客戶需求。

公司堅持的原則,"質(zhì)量優(yōu)先,客戶*,重信譽,塑口碑"。"品質(zhì)為金,誠信*,和諧發(fā)展與客戶共創(chuàng)雙贏,期待與您建立良好的業(yè)務(wù)關(guān)系。

小分子抑制劑,前列腺素,原料藥,醫(yī)藥中間體
CAS號 78919-13-8 產(chǎn)地 國產(chǎn)
級別 醫(yī)用級
伊洛前列素Iloprost (ZK 36374)是一種前列環(huán)素PGI2的合成類似物.
伊洛前列素 Iloprost 產(chǎn)品信息

伊洛前列素Iloprost (ZK 36374)是一種前列環(huán)素PGI2的合成類似物.

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2. Target: Iloprost is a stable prostacyclin analog commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in the presence of severe Raynaud's phenomenon (RP). [1] Iloprost dilates systemic and pulmonary arterial vascularbeds. Iloprost also affects platlet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.[2] Iloprost is a stable carbacyclin derivative of prostacyclin, was studied during electrically-induced coronary artery thrombosis in the open chest anesthetized pig. Infusion of ZK 36374 (100 ng/kg/min, n = 6) had no effect on heart rate and cardiac output, but caused a 20% reduction in mean arterial blood pressure by peripheral vasodilation. In animals receiving solvent or no drug prior to thrombosis induction, the time to occlusive coronary artery thrombosis (TOT) was 30 +/- 2 minutes (mean +/- SEM, n = 17). Pretreatment with an i.v. infusion of ZK 36374 (100 ng/kg/min) prolonged TOT by 50% to 47 +/- 7 minutes (p less than 0.005, n = 6). This prolongation of TOT was not due to the lower blood pressure in the ZK 36374 group, as dihydralazine in a dose that lowered arterial blood pressure to the same extent had no effect on TOT (32 +/- 4 minutes, n = 4). The results indicate that ZK 36374 may be useful in delaying (or preventing) occlusive coronary artery thrombi. 

同類產(chǎn)品推薦
在找 伊洛前列素 Iloprost 產(chǎn)品的人還在看

提示

×

*您想獲取產(chǎn)品的資料:

以上可多選,勾選其他,可自行輸入要求

個人信息: